Literature DB >> 16757145

Synergistic effect of polyoxometalates in combination with oxacillin against methicillin-resistant and vancomycin-resistant Staphylococcus aureus: a high initial inoculum of 1 x 108 cfu/ml for in vivo test.

M Inoue1, T Suzuki, Y Fujita, M Oda, N Matsumoto, J Iijima, T Yamase.   

Abstract

Synergistic effect of polyoxometalates, K(6)[P(2)W(18)O(62)].14H(2)O (P(2)W(18)), K(4)[SiMo(12)O(40)].3H(2)O (SiMo(12)), K(7)[PTi(2)W(10)O(40)].6H(2)O (PTi(2)W(10)), and K(9)H(5)[alpha-Ge(2)Ti(6)W(18)O(77)].16H(2)O (Ge(2)Ti(6)W(18)), in combination with a beta-lactam oxacillin against methicillin-resistant and vancomycin-resistant Staphylococcus aureus (characterized by possessing the penicillin-binding protein 2' (PBP2') as a cell-wall synthesis enzyme) with a high initial inoculum of 1 x 10(8) cfu/ml (for in vivo test) was investigated with a help of the growth curve and the reverse transcription polymerase chain reaction (RT-PCR) analyses. The growth curves showing the suppression of cell proliferation of the strains based on the synergistic effect of the polyoxometalates in combination with oxacillin indicated a recovery of the cell proliferation during continuous cultivation. The duration of the suppression of the cell proliferation increased with increasing the concentration of the polyoxometalates, depending on the amounts of the initial inoculum of the strain. The RT-PCR results for P(2)W(18), SiMo(12), and PTi(2)W(10) indicated the suppression of expression of the PBP2'-encoding mecA gene in contrast to the ones for Ge(2)Ti(6)W(18). The difference in the RT-PCR results among the polyoxometalates suggests that there remain other factors for the inhibition of PBP2' production such as post-transcription process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757145     DOI: 10.1016/j.biopha.2006.04.006

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics.

Authors:  Saira Khan; Anne Tøndervik; Håvard Sletta; Geir Klinkenberg; Charlotte Emanuel; Edvar Onsøyen; Rolf Myrvold; Robin A Howe; Timothy R Walsh; Katja E Hill; David W Thomas
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

2.  Hybrid Antimicrobial Films Containing a Polyoxometalate-Ionic Liquid.

Authors:  Ana G Enderle; Isabel Franco-Castillo; Elena Atrián-Blasco; Rafael Martín-Rapún; Leonardo Lizarraga; María J Culzoni; Mariela Bollini; Jesús M de la Fuente; Filomena Silva; Carsten Streb; Scott G Mitchell
Journal:  ACS Appl Polym Mater       Date:  2022-04-12

3.  In vivo toxicity evaluation of two polyoxotungstates with potential antidiabetic activity using Wistar rats as a model system.

Authors:  Marko Dinčić; Mirjana B Čolović; Marija Sarić Matutinović; Mila Ćetković; Tamara Kravić Stevović; Ali S Mougharbel; Jasna Todorović; Svetlana Ignjatović; Branimir Radosavljević; Milan Milisavljević; Ulrich Kortz; Danijela Z Krstić
Journal:  RSC Adv       Date:  2020-01-15       Impact factor: 3.361

Review 4.  Promising application of polyoxometalates in the treatment of cancer, infectious diseases and Alzheimer's disease.

Authors:  Xuechen Wang; Shengnan Wei; Chao Zhao; Xin Li; Jin Jin; Xuening Shi; Zhenyue Su; Juan Li; Juan Wang
Journal:  J Biol Inorg Chem       Date:  2022-06-17       Impact factor: 3.862

5.  Multicomponent therapeutics of berberine alkaloids.

Authors:  Jiaoyang Luo; Dan Yan; Meihua Yang; Xiaoping Dong; Xiaohe Xiao
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

Review 6.  Polyoxometalates active against tumors, viruses, and bacteria.

Authors:  Toshihiro Yamase
Journal:  Prog Mol Subcell Biol       Date:  2013

7.  In Vitro Antibacterial Susceptibility of Different Pathogens to Thirty Nano-Polyoxometalates.

Authors:  Ștefana Bâlici; Dan Rusu; Emőke Páll; Miuța Filip; Flore Chirilă; Gheorghe Zsolt Nicula; Mihaela Laura Vică; Rodica Ungur; Horea Vladi Matei; Nicodim Iosif Fiț
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.